A Propensity Score Matching Study on the Effect of OnabotulinumtoxinA Alone versus Short-Term Psychodynamic Psychotherapy Plus Drug-of-Choice as Preventive Therapy in Chronic Migraine: Effects and Predictive Factors
Michele Alessiani(Università Campus Bio-Medico), Vittorio Di Piero(Sapienza University of Rome), Rita De Sanctis(Humanitas University), E Gilliéron(University of Florence), Marta Puma, Alessandro Viganò(Sapienza University of Rome), Chiara‐Camilla Derchi(Don Carlo Gnocchi Foundation), Barbara Petolicchio(Policlinico Umberto I), Ciro Franzese(IRCCS Humanitas Research Hospital), Martina Squitieri(Agenzia Regionale di Sanità della Toscana), Massimiliano Toscano(Fatebenefratelli Hospital), Romina Di Giambattista(Istituto Psicoanalitico per le Ricerche Sociali)
Cited by 6
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
|European Journal of Nuclear Medicine and Molecular Imaging|2019|150